EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Reinvigorating drug development around NGF signaling for pain

Andi Wangzhou, Theodore J Price

Journal of Clinical Investigation · 17.02.2025 · 135 (4)

DOI: 10.1172/jci189029 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 17.02.2025. Verfasst von Andi Wangzhou und 1 weiteren Autor:innen. Hauptthemen laut MEDLINE: Nerve Growth Factor, Signal Transduction, Receptor, trkA, Drug Development. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nerve growth factor (NGF) signaling is a clinically validated target for the treatment of several prevalent types of chronic pain; however, addressing safety concerns remain a key challenge. In this issue of the JCI , Peach et al. take a major step forward in this area by deciphering complexities in the signaling of the NGF receptor TrkA, finding that neuropilin 1 (NRP1) acted as a coreceptor for NGF actions at TrkA and the receptor complex required scaffolding from GIPC1. Using a mix of techniques, including animal behavioral models, electrophysiology on mouse and human dorsal root ganglion (DRG) neurons, and elegant biochemical pharmacology, the authors demonstrated that this therapeutic target might more safely manipulate NGF signaling to achieve pain alleviation. While there are still important questions to answer, the innovative work paves the way for the development of nonopioid pain therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nerve Growth FactorSignal TransductionReceptor, trkADrug DevelopmentPainChronic PainHumansAnimalsMiceNeuropilin-1Ganglia, Spinal

Substanzen

Nerve Growth FactorReceptor, trkANeuropilin-1NGF protein, humanNTRK1 protein, human

Förderung

  • NINDS NIH HHS

Zitieren

APA

Wangzhou, A., & Price, T. J. (2025). Reinvigorating drug development around NGF signaling for pain. Journal of Clinical Investigation, 135(4). https://doi.org/10.1172/jci189029

Vancouver

Wangzhou A, Price TJ. Reinvigorating drug development around NGF signaling for pain. Journal of Clinical Investigation. 2025;135(4). doi:10.1172/jci189029

BibTeX
@article{Wangzhou2025,
  author = {Wangzhou, Andi and Price, Theodore J},
  title = {Reinvigorating drug development around NGF signaling for pain},
  journal = {Journal of Clinical Investigation},
  year = {2025},
  volume = {135},
  number = {4},
  doi = {10.1172/jci189029}
}
Kostenlos starten →